Last reviewed · How we verify
Thrombocytosis in Myeloproliferative Disease
Approved treatments
- Agrylin · Takeda
Agrylin works by inhibiting an enzyme that regulates platelet production, leading to a decrease in platelet count.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Thrombocytosis in Myeloproliferative Disease patent landscape — cliff calendar, originator estates, attackable patents
- Thrombocytosis in Myeloproliferative Disease treatment landscape brief
- Thrombocytosis in Myeloproliferative Disease treatment updates RSS
Frequently asked questions about Thrombocytosis in Myeloproliferative Disease
What drugs treat Thrombocytosis in Myeloproliferative Disease?
Tracked treatments include Agrylin.
What is the treatment for Thrombocytosis in Myeloproliferative Disease?
Standard treatment for Thrombocytosis in Myeloproliferative Disease includes Agrylin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Thrombocytosis in Myeloproliferative Disease patent cliff · Thrombocytosis in Myeloproliferative Disease CI report
- Treatment: Agrylin · Takeda
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing